As a result, drugs that target various metabolic enzymes, such as dihydrofolate reductase (DHFR) and fatty acid synthase (FASN), have either been approved for clinical use or are currently in clinical trials for the treatment of various solid tumors, including colorectal, gastric, breast, and lung cancer (4). This evidence concerns the gene DHFR and lung carcinoma.